Floatz logo

Hucart-Meso Cells

Mesotheliomas Pleural

University of PennsylvaniaCell therapyPhase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Mesotheliomas Pleural cohort.

Asset / SponsorPhaseRating
Eflornithine
Aminex Therapeutics, Inc.
Phase 1/2CCC
Nivolumab
TCR2 Therapeutics
Phase 1/2CCC
tc-510
TCR2 Therapeutics
Phase 1/2CCC
Ipilimumab
TCR2 Therapeutics
Phase 1/2CCC
Cyclophosphamide
TCR2 Therapeutics
Phase 1/2CCC

View all 12 →

Same molecule, other indications

Hucart-Meso Cells is also rated in:

peritoneal mesotheliomaDormant
C
Indicative ·
39 / 100
View asset →
peritoneal carcinomaDormant
C
Indicative ·
39 / 100
View asset →
lung adenocarcinomaDormant
C
Indicative ·
38 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →